Targeting the bone marrow niche in hemoglobinopathies.

[1]  M. Lidonnici,et al.  Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche. , 2019, Blood.

[2]  S. Rivella,et al.  Gene therapy of hemoglobinopathies: progress and future challenges. , 2019, Human molecular genetics.

[3]  A. Aprile,et al.  Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity , 2019, The Journal of clinical investigation.

[4]  B. Shetty,et al.  Prevalence of Hypoparathyroidism (HPT) in Beta Thalassemia Major. , 2014, Journal of clinical and diagnostic research : JCDR.

[5]  E. Shpall,et al.  Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  G. Lucarelli,et al.  Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. , 2012, Cold Spring Harbor perspectives in medicine.

[7]  I. Bernstein,et al.  Notch2 governs the rate of generation of mouse long- and short-term repopulating stem cells. , 2011, The Journal of clinical investigation.

[8]  Y. Ko,et al.  Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size , 2005, The Journal of experimental medicine.

[9]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[10]  C. Quinn,et al.  Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease. , 2017, Advances in experimental medicine and biology.